CeptarisCeptaris CompanyCeptaris Investigational DrugCeptaris NewsCeptaris Contact Us  
       
       
   
 
 
     
  Top News  
  RSS Feed  
     

MEDIA INQUIRIES
Mike Beyer
Sam Brown Inc.
Phone: 773-463-4211
beyer@sambrown.com 
 

 


PRESS RELEASES

September 19, 2013
Actelion closes acquisition of privately-held Ceptaris Therapeutics adding Valchlor to Actelion’s product portfolio
Valchlor™ is the only FDA-approved topical formulation of mechlorethamine
US launch planned for Q4 2013
US patient support and assistance programs will be available for Valchlor

August 26, 2013
Ceptaris Receives FDA Approval for VALCHLOR™ (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
First and only FDA-approved topical formulation of mechlorethamine (nitrogen mustard)
Patient support and assistance programs to be established for VALCHLOR

July 31, 2013
Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics
VALCHLOR™ gel under FDA Review for Early-Stage Mycosis Fungoides-Type CTCL

February 27, 2013
Ceptaris Resubmits New Drug Application (NDA) to FDA for Proprietary Gel Formulation of Mechlorethamine Hydrochloride

January 30, 2013
Ceptaris Announces Publication in JAMA Dermatology of Positive Clinical Results for Mechlorethamine Gel in Early Stage Mycosis Fungoides, The Most Common Type of Cutaneous T-Cell Lymphoma

June 05, 2012
CEPTARIS SECURES $10 MILLION IN SERIES D-1 FINANCING

February 21, 2012
CEPTARIS SECURES $15M IN VENTURE DEBT FINANCING

January 18, 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel

January 05, 2012
Yaupon Changes Name to Ceptaris Therapeutics, Inc.

October 04, 2011
FDA Accepts Filing of New Drug Application (NDA) for Yaupon's Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Yaupon seeking U.S. marketing approval for topical treatment for early stage (stages I-IIA) mycosis fungoides, a common type of Cutaneous T-Cell Lymphoma

August 11, 2011
Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D. Financing

July 28, 2011
Yaupon Therapeutics, Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Requesting U.S. marketing approval for the topical treatment of early stage (stages I-IIA) mycosis fungoides, a common type of Cutaneous T-Cell Lymphoma

July 18, 2011
Yaupon Therapeutics, Inc. Appoints New Management Team
New management to focus on NDA submission for proprietary gel formulation of mechlorethamine hydrochloride to treat early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma

May 9, 2011
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer

September 24, 2010
Yaupon Announces Results from Pivotal Study

 

 

 

 

 

 

 
   
     
 
   
   
   
   
         
print page